- Home
- SDSTW vs ICU Comparison
SDSTW vs ICU Comparison
Compare SDSTW & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDSTW | ICU |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 9.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SDSTW | ICU |
|---|---|---|
| Price | $0.16 | $4.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.4K | ★ 102.3K |
| Earning Date | 03-26-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.22 |
| 52 Week High | $0.30 | $4.93 |
Technical Indicators
Market Signals| Indicator | SDSTW | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 59.95 |
| Support Level | $0.15 | $2.26 |
| Resistance Level | $0.23 | $4.89 |
| Average True Range (ATR) | 0.02 | 0.37 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 63.83 | 62.80 |
Price Performance
Historical ComparisonAbout SDSTW Stardust Power Inc. Warrant
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.